Showing results (11-20 of 47) with videos related to

Sort By:
Pageof 5
Clinical Pharmacology and Therapeutics|February 22, 2008
Renal function as a predictor of irinotecan-induced neutropeniaF A de Jong, J M van der Bol, R H J Mathijssen, et al.
Plos One|February 1, 2024
Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumabR J S D Heine, F W Thielen, R H J Mathijssen, et al.
ESMO Open|March 29, 2023
Implementation of dihydropyrimidine dehydrogenase deficiency testing in EuropeM de With, A Sadlon, E Cecchin, et al.
British Journal of Cancer|February 16, 2013
Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugsR W F van Leeuwen, D H S Brundel, C Neef, et al.
Frontiers in Immunology|February 22, 2021
Case Report: Adequate T and B Cell Responses in a SARS-CoV-2 Infected Patient After Immune Checkpoint InhibitionK de Joode, A A M Oostvogels, C H GeurtsvanKessel, et al.
British Journal of Cancer|March 6, 2015
Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitorsJ S L Kloth, A Pagani, M C Verboom, et al.
British Journal of Pharmacology|January 14, 2010
Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2)H Burger, A Zoumaro-Djayoon, A W M Boersma, et al.
European Journal of Cancer (Oxford, England : 1990)|September 28, 2019
Pemetrexed exposure predicts toxicity in advanced non-small-cell lung cancer: A prospective cohort studyS Visser, S L W Koolen, P de Bruijn, et al.
The Pharmacogenomics Journal|April 15, 2015
Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication studyD J Crona, J Ramirez, W Qiao, et al.
Clinical Pharmacology and Therapeutics|April 22, 2011
Environmental and genetic factors affecting transport of imatinib by OATP1A2K Eechoute, R M Franke, W J Loos, et al.
Pageof 5